14th April 2022 | Pharma Updates
Biological E was asked for more information about Corbevax for children aged 5 to 12
Biological E, a Hyderabad-based pharmaceutical business, has sought for an Emergency Use Authorization (EUA) for its COVID-19 vaccine Corbevax for children aged 5 to 12.
Zydus would deliver goods to US firm Sagent from its Gujarat factory
Zydus Lifesciences announced that it will deliver Caffeine Citrate Oral Solution from its Gujarat-based production plant to US-based Sagent Pharmaceuticals, Inc.
Bharat Bio partner Ocugen discontinue Covaxin testing
USFDA informed the business that its phase 2/3 immuno-bridging and widening research for Covaxin (BBV152), OCU-002, had been placed on clinical hold.
Local pharmaceutical companies now have easier access to launching goods in Australia
The Therapeutic Goods Administration, Australia’s drug regulatory authority, has agreed to accelerate speedier and easier approvals for India’s generic pharmaceutical items that have already been licenced.
Novartis intends to lay off thousands of employees
Novartis has confirmed that it intends to reduce its headcount as part of a restructuring initiative announced last week, but has declined to provide a figure for the cuts.
Amneal Pharmaceuticals receives FDA approval for Alymsys
Amneal Pharmaceuticals has received FDA clearance for its biologics licence application for bevacizumab-maly, a biosimilar to Swiss manufacturer Roche Holding’s cancer medicine Avastin.
Biofrontera Inc. announces FDA approval of Biofrontera Pharma GmbH
Biofrontera stated that the FDA has certified Biofrontera Pharma’s cGMP facility in Leverkusen, Germany, as a contract laboratory for batch control and stability testing of Ameluz.
